Related references
Note: Only part of the references are listed.Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma
Barak Pertzov et al.
JOURNAL OF ASTHMA (2021)
Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety
Jermo Johannes van Toor et al.
JOURNAL OF ASTHMA (2021)
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
Moritz Z. Kayser et al.
JOURNAL OF ASTHMA AND ALLERGY (2021)
Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma A Delphi Study
Carey M. Suehs et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis
Hongwen Li et al.
CLINICAL THERAPEUTICS (2021)
Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot
Claudia Crimi et al.
RESPIRATORY MEDICINE (2021)
Biological therapy-associated adverse reactions in asthma: analysis of reporting to the Portuguese pharmacovigilance system
Jose Sousa et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Blood eosinophil count in the general population: typical values and potential confounders
Sylvia Hartl et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma
Grainne d'Ancona et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Mepolizumab effectiveness and identification of super-responders in severe asthma
Erin S. Harvey et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Real-World Effectiveness and the Characteristics of a Super-Responder to Mepolizumab in Severe Eosinophilic Asthma
Joanne E. Kavanagh et al.
CHEST (2020)
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype
Corrado Pelaia et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Real-word experience with mepolizumab: Does it deliver what it has promised?
Florence Schleich et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2020)
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
Camille Taille et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life
Bruno Sposato et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic
David Langton et al.
RESPIROLOGY (2020)
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting
Paolo Cameli et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2020)
Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study
Insu Yilmaz et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2020)
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
Jean-Pierre Llanos et al.
JOURNAL OF ASTHMA AND ALLERGY (2020)
Moving forward from drug-centred to patient-centred research
Denis Lacombe et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life
Carlo Lombardi et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2019)
Mepolizumab improves small airway function in severe eosinophilic asthma
Claude S. Farah et al.
RESPIRATORY MEDICINE (2019)
Biological treatments for severe asthma: A major advance in asthma care
William W. Busse
ALLERGOLOGY INTERNATIONAL (2019)
The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group
Nicolas Roche et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
One year of mepolizumab. Efficacy and safety in real-life in Italy
Diego Bagnasco et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2019)
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response
Marco Caminati et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2019)
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
Sumita Khatri et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response
Nora Drick et al.
BMC PULMONARY MEDICINE (2018)
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study
Corrado Pelaia et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Theo Vos et al.
LANCET (2017)
Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis
Naweed I. Chowdhury et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Njira Lugogo et al.
CLINICAL THERAPEUTICS (2016)
Are Asthmatics Enrolled in Randomized Trials Representative of Real-Life Outpatients?
Salvatore Battaglia et al.
RESPIRATION (2015)
Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases
Francesco Menzella et al.
JOURNAL OF ASTHMA AND ALLERGY (2015)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
Hector Ortega et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Severe asthma: from characteristics to phenotypes to endotypes
S. Wenzel
CLINICAL AND EXPERIMENTAL ALLERGY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Influence of comorbid conditions on asthma
L-P. Boulet
EUROPEAN RESPIRATORY JOURNAL (2009)
The minimally important difference of the Asthma Control Test
Michael Schatz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Share Paper
